Teprotumumab for Asymmetric Thyroid Eye Disease

Ophthalmology. 2021 Oct;128(10):1416. doi: 10.1016/j.ophtha.2021.03.004.

Authors

Shoaib Ugradar¹, Yao Wang², Raymond Douglas²

Affiliations

¹ Jules Stein Eye Institute, Division of Orbital and Oculoplastic Surgery, University of California, Los Angeles, Los Angeles, California.
² Oculoplastics, Cedars Sinai Hospital, Los Angeles, California.

PMID: 34556309
DOI: 10.1016/j.ophtha.2021.03.004

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized / administration & dosage*
Female
Graves Ophthalmopathy / diagnosis
Graves Ophthalmopathy / drug therapy*
Humans
Infusions, Intravenous
Middle Aged
Thyroid Gland / diagnostic imaging*

Substances

Antibodies, Monoclonal, Humanized
teprotumumab